Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GE HealthCare Technologies Inc. (GEHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on Nasdaq under the symbol GEHC, GE HealthCare submits periodic and current reports that offer detail on its financial condition, governance, and significant corporate events.
Among the key documents investors often review are Form 10-K annual reports and Form 10-Q quarterly reports, which contain information on the company’s operations across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. In addition, Form 8-K current reports disclose material events. Recent 8-K filings have described items such as a three-year senior unsecured term loan credit facility, the issuance of senior notes due 2028 and 2035, the intended use of proceeds in connection with an announced acquisition of Intelerad Medical Systems, quarterly financial results, and changes to the board of directors.
Investors interested in GEHC can also use this page to track other filing types, such as registration statements and, when applicable, proxy materials related to governance matters. These documents help explain the company’s capital structure, including senior notes and credit facilities, and outline covenants, events of default, and other terms referenced in the filings.
Stock Titan enhances access to GE HealthCare’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points in lengthy documents. This can help users quickly understand the implications of new 10-K, 10-Q, and 8-K filings, as well as monitor developments related to financing arrangements, acquisitions, and other significant events disclosed by GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. Chief Accounting Officer George A. Newcomb reported equity awards from the company. He received an employee stock option for 3,443 shares of common stock at an exercise price of $0.00 per share, and an award of 1,309 restricted stock units, each representing one share of common stock at settlement.
According to the award terms, 33% of the restricted stock units will vest on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. The stock option becomes exercisable on the same schedule: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. After these transactions, he directly owned 10,627 shares of common stock and had an additional 12 shares held indirectly by a family member.
GE HealthCare Technologies reported that Kevin Michael O'Neill, CEO of PDx, received equity awards on March 2, 2026. He was granted 17,218 employee stock options at an exercise price of $0.00 per share and 6,549 shares of common stock as a stock award, all held directly.
The options will become exercisable in three installments of 33%, 33%, and 34% on September 2, 2027, September 2, 2028, and September 2, 2029. A separate restricted stock unit award will vest on the same 33%, 33%, 34% schedule. O'Neill also has 59 shares held indirectly through a share incentive plan trust.
Rackliffe Philip reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. granted equity awards to executive Philip Rackliffe, CEO of AVS. He received 24,598 employee stock options with a right to buy GE HealthCare common stock and 9,356 restricted stock units, each representing one share upon settlement.
The stock options and restricted stock units vest over three years, with 33% vesting or becoming exercisable on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. These awards are part of his direct ownership and represent compensation rather than open-market purchases.
GE HealthCare Technologies Inc. reported that Roland Rott, CEO of Imaging, received new equity awards. He was granted employee stock options for 22,548 shares at an exercise price of $0.00 per share and 8,576 shares of common stock as a stock-based award.
The restricted stock units for 8,576 shares will vest in stages, with 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The 22,548 stock options follow the same 33%/33%/34% exercisability schedule on those dates.
SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Financial Officer James Saccaro received equity awards on March 2, 2026. He was granted 32,797 employee stock options and 12,475 restricted stock units, each at a price of $0.00 per unit.
The restricted stock units vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options become exercisable on the same 33%/33%/34% schedule over those dates. Following the stock award, Saccaro directly holds 84,161 shares of common stock and 32,797 options.
Arduini Peter J reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that President and CEO Peter J. Arduini received new equity awards. He was granted an employee stock option covering 129,140 shares of GE HealthCare common stock and 49,120 restricted stock units, each representing one share of common stock at settlement.
According to the vesting schedule, 33% of both the restricted stock units and the stock options will vest or become exercisable on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. Following the stock grant, Arduini directly owned 255,255 shares of common stock.
GE HealthCare Technologies Inc. entered into a new 364-day senior unsecured revolving credit agreement for $0.5 billion with JPMorgan Chase Bank and other lenders. This revolving credit facility matures on February 25, 2027 and can be drawn in U.S. Dollars, Euros, or Pound Sterling.
Borrowings bear interest at benchmark rates such as SOFR, EURIBOR, or SONIA, plus a margin tied to the company’s senior unsecured long-term debt ratings. The agreement includes customary covenants on liens, certain corporate transactions, leverage, and subsidiary indebtedness, along with standard events of default.
The new facility replaces a prior $0.5 billion 364-day revolving credit agreement dated March 27, 2025, which was terminated without penalty on February 26, 2026.
GE HealthCare Technologies Chief Accounting Officer George A. Newcomb reported equity compensation activity tied to performance stock units. On February 12, 2026, he acquired 2,523 shares of common stock at $0 per share when PSUs granted on March 1, 2023 vested after performance criteria were certified.
On the same date, 802 shares at $79.2 per share were withheld to cover tax obligations arising from the PSU vesting, a non-market disposition. After these transactions, he directly owned 9,318 shares of common stock and indirectly held 12 additional shares through a family member.
GE HealthCare Technologies Inc. CEO Kevin Michael O'Neill reported equity award activity in company stock. On February 12, 2026, he acquired 6,938 shares of common stock at $0 per share through the vesting of previously granted performance stock units after performance criteria were certified.
To cover related tax withholding obligations from this vesting, 3,261 shares were disposed of at a price of $79.2 per share. Following these transactions, O'Neill directly held 26,195 shares of GE HealthCare common stock and indirectly held 59 shares through a share incentive plan trust.
GE HealthCare Technologies Inc. CEO Philip Rackliffe reported equity transactions tied to performance stock units (PSUs). On February 12, 2026, 3,154 shares of common stock were acquired at $0 per share upon PSU vesting after performance criteria were certified.
To cover related tax obligations, 1,174 shares were disposed of through a tax-withholding transaction at $79.2 per share. Following these transactions, Rackliffe directly owned 17,373 shares of GE HealthCare common stock.